319 related articles for article (PubMed ID: 29475458)
21. Management of patients with primary central nervous system lymphoma treated with high-dose methotrexate.
Warnick E; Auger D
Clin J Oncol Nurs; 2009 Apr; 13(2):177-80. PubMed ID: 19349264
[TBL] [Abstract][Full Text] [Related]
22. Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections.
Wright KD; Panetta JC; Onar-Thomas A; Reddick WE; Patay Z; Qaddoumi I; Broniscer A; Robinson G; Boop FA; Klimo P; Ward D; Gajjar A; Stewart CF
Cancer Chemother Pharmacol; 2015 Jan; 75(1):27-35. PubMed ID: 25342291
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic management of primary central nervous system lymphoma: lessons from prospective trials.
Ferreri AJ; Reni M; Villa E
Ann Oncol; 2000 Aug; 11(8):927-37. PubMed ID: 11038028
[TBL] [Abstract][Full Text] [Related]
24. Analysis of Key Factors Associated with Response to Salvage High-Dose Methotrexate Rechallenge in Primary Central Nervous System Lymphoma with First Relapse.
Du P; Chen H; Shen L; Liu X; Wu X; Chen L; Cao A; Geng D
Curr Oncol; 2022 Sep; 29(9):6642-6656. PubMed ID: 36135091
[TBL] [Abstract][Full Text] [Related]
25. Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas.
Ferreri AJ; Guerra E; Regazzi M; Pasini F; Ambrosetti A; Pivnik A; Gubkin A; Calderoni A; Spina M; Brandes A; Ferrarese F; Rognone A; Govi S; Dell'Oro S; Locatelli M; Villa E; Reni M
Br J Cancer; 2004 Jan; 90(2):353-8. PubMed ID: 14735176
[TBL] [Abstract][Full Text] [Related]
26. Comparison of Body Size, Morphomics, and Kidney Function as Covariates of High-Dose Methotrexate Clearance in Obese Adults with Primary Central Nervous System Lymphoma.
Pai MP; Debacker KC; Derstine B; Sullivan J; Su GL; Wang SC
Pharmacotherapy; 2020 Apr; 40(4):308-319. PubMed ID: 32090349
[TBL] [Abstract][Full Text] [Related]
27. Stereotactic radiosurgery in combination with up-front high-dose methotrexate as a first-line treatment for newly diagnosed primary central nervous system lymphoma.
Hirono S; Iwadate Y; Higuchi Y; Serizawa T; Nagano O; Matsutani T; Saeki N
J Neurooncol; 2015 Jun; 123(2):237-44. PubMed ID: 25911295
[TBL] [Abstract][Full Text] [Related]
28. High-dose methotrexate monotherapy for newly diagnosed primary central nervous system lymphoma: 15-year multicenter experience.
Yoon WS; Park JS; Kim YI; Chung DS; Jeun SS; Hong YK; Yang SH
Asia Pac J Clin Oncol; 2021 Feb; 17(1):123-130. PubMed ID: 32978898
[TBL] [Abstract][Full Text] [Related]
29. Long-term survival in AIDS-related primary central nervous system lymphoma.
Gupta NK; Nolan A; Omuro A; Reid EG; Wang CC; Mannis G; Jaglal M; Chavez JC; Rubinstein PG; Griffin A; Abrams DI; Hwang J; Kaplan LD; Luce JA; Volberding P; Treseler PA; Rubenstein JL
Neuro Oncol; 2017 Jan; 19(1):99-108. PubMed ID: 27576871
[TBL] [Abstract][Full Text] [Related]
30. Delayed methotrexate elimination in a patient with primary central nervous system lymphoma: A case report.
Urata S; Yoshikawa N; Saito K; Tazaki T; Ohno R; Takeshima H; Ikeda R
J Clin Pharm Ther; 2021 Dec; 46(6):1796-1799. PubMed ID: 34008211
[TBL] [Abstract][Full Text] [Related]
31. Mechanisms of methotrexate resistance in acute leukemia. Decreased transport and polyglutamylation.
Gorlick R; Cole P; Banerjee D; Longo G; Li WW; Hochhauser D; Bertino JR
Adv Exp Med Biol; 1999; 457():543-50. PubMed ID: 10500832
[TBL] [Abstract][Full Text] [Related]
32. Treatment of Primary Central Nervous System Lymphoma with High-dose Methotrexate and Radiotherapy in HIV-negative Patients.
Jalaeikhoo H; Yekaninejad MS; Hajizamani S; Rahim F; Ahmadzadeh A; Keyhani M; Sadeghi Hariri B; Saki N
Arch Iran Med; 2015 Sep; 18(9):577-81. PubMed ID: 26317598
[TBL] [Abstract][Full Text] [Related]
33. Non-deep-seated primary CNS lymphoma: therapeutic responses and a molecular signature.
Iwadate Y; Suganami A; Ikegami S; Shinozaki N; Matsutani T; Tamura Y; Saeki N; Yamanaka R
J Neurooncol; 2014 Apr; 117(2):261-8. PubMed ID: 24488444
[TBL] [Abstract][Full Text] [Related]
34. High-dose methotrexate and rituximab induction regimen in immunocompetent patients with primary CNS lymphoma: a retrospective single-center study of survival predictors.
DeAtkine AB; Abdelrashid M; Tucker Z; Mehta A; Markert JM; Kim J; Fiveash JB; Oster RA; Lobbous M; Nabors LB
J Neurooncol; 2022 May; 158(1):33-40. PubMed ID: 35441948
[TBL] [Abstract][Full Text] [Related]
35. Population Pharmacokinetics of High-Dose Methotrexate in Patients With Primary Central Nervous System Lymphoma.
Mei S; Li X; Jiang X; Yu K; Lin S; Zhao Z
J Pharm Sci; 2018 May; 107(5):1454-1460. PubMed ID: 29331383
[TBL] [Abstract][Full Text] [Related]
36. Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survival.
Martinez-Calle N; Poynton E; Alchawaf A; Kassam S; Horan M; Rafferty M; Kelsey P; Scott G; Culligan DJ; Buckley H; Lim YJ; Ngu L; McCulloch R; Rowntree C; Wright J; McKay P; Fourali S; Eyre TA; Smith J; Osborne W; Yallop D; Linton K; Fox CP; Cwynarski K
Br J Haematol; 2020 Aug; 190(3):394-404. PubMed ID: 32232989
[TBL] [Abstract][Full Text] [Related]
37. Relapse of primary central nervous system lymphoma 13 years after high-dose methotrexate-based polychemotherapy.
Steinbeck JA; Stuplich M; Blasius E; Pels H; Glas M; Schlegel U; Herrlinger U
J Clin Neurosci; 2011 Nov; 18(11):1554-5. PubMed ID: 21868233
[TBL] [Abstract][Full Text] [Related]
38. Prognostic impact of completion of initial high-dose methotrexate therapy on primary central nervous system lymphoma: a single institution experience.
Makino K; Nakamura H; Hide T; Kuroda J; Yano S; Kuratsu J
Int J Clin Oncol; 2015 Feb; 20(1):29-34. PubMed ID: 24722885
[TBL] [Abstract][Full Text] [Related]
39. Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas.
Ferreri AJ; Dell'Oro S; Capello D; Ponzoni M; Iuzzolino P; Rossi D; Pasini F; Ambrosetti A; Orvieto E; Ferrarese F; Arrigoni G; Foppoli M; Reni M; Gaidano G
Br J Haematol; 2004 Sep; 126(5):657-64. PubMed ID: 15327516
[TBL] [Abstract][Full Text] [Related]
40. High-dose methotrexate for intraocular lymphoma.
Batchelor TT; Kolak G; Ciordia R; Foster CS; Henson JW
Clin Cancer Res; 2003 Feb; 9(2):711-5. PubMed ID: 12576439
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
